Euroespes, S.A., a medical center, provides medical services for the prevention, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. More Details
Adequate balance sheet and overvalued.
Share Price & News
How has Euroespes's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EEP has not had significant price volatility in the past 3 months.
7 Day Return
ES Life Sciences
1 Year Return
ES Life Sciences
Return vs Industry: EEP underperformed the Spanish Life Sciences industry which returned 70.1% over the past year.
Return vs Market: EEP matched the Spanish Market which returned -26.6% over the past year.
Price Volatility Vs. Market
How volatile is Euroespes's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 months ago | Simply Wall StWhat Type Of Shareholder Owns Euroespes, S.A.'s (BME:EEP)?
6 months ago | Simply Wall StIs Euroespes (BME:EEP) A Risky Investment?
8 months ago | Simply Wall StImagine Owning Euroespes (BME:EEP) And Wondering If The 30% Share Price Slide Is Justified
Is Euroespes undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EEP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EEP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EEP is unprofitable, so we can't compare its PE Ratio to the XE Life Sciences industry average.
PE vs Market: EEP is unprofitable, so we can't compare its PE Ratio to the Spanish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EEP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EEP is good value based on its PB Ratio (0.7x) compared to the XE Life Sciences industry average (5.2x).
How is Euroespes forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Euroespes has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Euroespes's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Euroespes competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Euroespes performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EEP is currently unprofitable.
Growing Profit Margin: EEP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EEP is unprofitable, and losses have increased over the past 5 years at a rate of 66.7% per year.
Accelerating Growth: Unable to compare EEP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EEP is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (28.5%).
Return on Equity
High ROE: EEP has a negative Return on Equity (-17.99%), as it is currently unprofitable.
How is Euroespes's financial position?
Financial Position Analysis
Short Term Liabilities: EEP's short term assets (€3.0M) exceed its short term liabilities (€1.7M).
Long Term Liabilities: EEP's short term assets (€3.0M) exceed its long term liabilities (€2.2M).
Debt to Equity History and Analysis
Debt Level: EEP's debt to equity ratio (37.9%) is considered satisfactory.
Reducing Debt: EEP's debt to equity ratio has reduced from 58.4% to 37.9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if EEP has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if EEP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Euroespes's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EEP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EEP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EEP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EEP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EEP's dividend in 3 years as they are not forecast to pay a notable one for the Spanish market.
How experienced are the management team and are they aligned to shareholders interests?
Euroespes has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Euroespes, S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Euroespes, S.A.
- Ticker: EEP
- Exchange: BME
- Founded: 1991
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: €4.683m
- Shares outstanding: 10.55m
- Website: https://www.euroespes.com
Number of Employees
- Euroespes, S.A.
- Santa Marta de Babío s/n
- A Coruña
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EEP||BME (Bolsas y Mercados Espanoles)||Yes||Share Capital||ES||EUR||Feb 2011|
Euroespes, S.A., a medical center, provides medical services for the prevention, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. The company of ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/30 20:33|
|End of Day Share Price||2020/10/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.